LOGIN  |  REGISTER
FILTER BY TOPIC:     Enrollment   Pre-Clinical   First Dose   Phase 1   Phase 1/2   Phase 2   Phase 2/3   Phase 3  

Bristol-Myers Squibb: New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in...

February 16
Last Trade: 53.90 -2.07 -3.70

No new safety signals observed at Year 5 in the POETYK PSO long-term extension trial, consistent with the established Sotyktu safety profile Following five years of continuous Sotyktu treatment, clinical response was maintained in nearly half of patients for Psoriasis Area and...Read more


Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination...

February 15
Last Trade: 35.00 0.51 1.48

After more than five years of follow-up, CABOMETYX in combination with Opdivo continued to show survival benefit compared with sunitinib Long-term efficacy seen across subgroups, including site of metastases ALAMEDA, Calif. / Feb 15, 2025 / Business Wire / Exelixis, Inc....Read more


IMFINZI® (durvalumab) perioperative regimen improved event-free survival and overall survival across muscle-invasive bladder...

February 14
Last Trade: 73.58 -0.87 -1.17

IMFINZI reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone WILMINGTON, Del. / Feb 14, 2025 / Business Wire / Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI®...Read more


Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

February 13
Last Trade: 14.74 -0.30 -1.99

First Major Technological Breakthrough in Hyaluronic Acid Dermal Fillers in a Decade; U.S. Launch Planned in Q2 2025 Launch Establishes Evolus as a Multi-Product Performance Beauty Company and Expands Addressable Market by 78% NEWPORT BEACH, Calif. / Feb 13, 2025 / Business Wire / Evolus, Inc....Read more


Moleculin Biotech Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R...

February 13
Last Trade: 2.18 0.91 71.65

Company remains on track for first subject treated in pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) in the first quarter of 2025 HOUSTON, Feb. 13, 2025 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company...Read more


FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)

February 12
Last Trade: 41.06 -0.23 -0.56

Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries Evrysdi tablet can be stored at room temperature and offers the same demonstrated efficacy and safety as the currently available oral solution New tablet formulation may provide greater freedom...Read more


Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. The company's lead cell therapy asset is NXC-201 in multiple myeloma...

CLICK TO LEARN MORE

Biggest Gainers

 
CompanyChangeLast Trade
Abbott 15.62 13.58 $130.61
West Pharmaceutical 15.49 7.78 $214.60
AbbVie 13.67 7.63 $192.87
Finch Therapeutics 13.20 733.33 $15.00
Glaukos 6.82 4.66 $153.20
CRISPR Therapeutics 6.36 14.62 $49.85
Ligand Pharmaceuticals 6.07 5.33 $120.00
Tempus AI 5.75 6.87 $89.50
DexCom 4.98 5.92 $89.07
Cytokinetics 4.54 10.91 $46.16
Intuitive Surgical 4.16 0.70 $595.55
Praxis Precision Medicines 4.11 4.74 $90.77
Beam Therapeutics 3.79 13.25 $32.40
ICON 3.57 1.95 $186.21
BridgeBio Pharma 3.34 10.58 $34.90
Absci 3.06 110.43 $5.83
Aligos Therapeutics 2.99 14.23 $24.00
Danaher 2.71 1.33 $206.30

Highest Volume

 
CompanyVolumeLast Trade
CNS Pharmaceuticals 480,732,013 $0.15
OS Therapies 244,230,691 $2.16
Moleculin Biotech 134,843,523 $2.18
Virpax Pharmaceuticals 118,886,367 $0.31
Petros Pharmaceuticals 106,063,818 $0.30
Aditxt 85,552,088 $0.07
81,151,781 $10.54
PacBio 45,559,729 $1.84
Allogene Therapeutics 42,238,673 $2.04
Ocean Biomedical 41,004,441 $0.13
KindlyMD 31,070,741 $2.94
Pfizer 25,448,679 $25.53
Tempus AI 24,864,184 $89.50
Moderna 24,662,791 $32.99
Merck 23,880,845 $83.01
Geron 22,737,482 $2.56
AEON Biopharma 21,871,017 $0.13
Senseonics 20,968,077 $1.24
Teladoc Health 20,183,792 $14.33
  • Upcoming FDA Catalysts

    • Bristol-Myers Squibb (NYSE: BMY) PDUFA Date

      February 28, 2025
    • Eton Pharmaceuticals (NASDAQ: ETON) PDUFA Date

      February 28, 2025
    • SpringWorks Therapeutics (NASDAQ: SWTX) PDUFA Date

      February 28, 2025
    • SpringWorks Therapeutics (NASDAQ: SWTX) PDUFA Date

      February 28, 2025
    • scPharmaceuticals (NASDAQ: SCPH) PDUFA Date

      March 6, 2025
    • Roivant (NASDAQ: ROIV) PDUFA Date

      March 12, 2025

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets...

CLICK TO LEARN MORE

Invest In Early-Stage Biotech Opportunities

  • Explore venture capital investment opportunities in the healthcare industry and gain direct access to deal flows

  • Private placement shares can generally be purchased at a discount to market prices and have purchase warrants attached to them

  • If the underlying share price rises, warrants can be exercised to further build positions and enhance gains

  • Sign up to receive notifications of future early-stage investment opportunities:
Edit